12 March 2026 | Thursday | News
dsm-firmenich, innovators in nutrition, health, and beauty, has announced the completion of a planned $10 million modernization program on its Schenectady premix facility in the United States, transforming the site into a flagship premix hub for the Americas. Engineered to set new benchmarks in quality standards, operational performance, and sustainability across human food, dietary supplements, and infant formula premix blends, the upgraded Schenectady facility gives customers greater confidence in an increasingly demanding regulatory and commercial environment.
A generational upgrade that redefines premix excellence
Schenectady now stands among the most advanced human health premix sites in North America, after being enhanced with optimized GMP zoning, improved material flow, and expanded material conditioning capabilities via cutting-edge advanced powder technologies. The reinvention was designed with customers firmly in mind: strengthening quality assurance, improving operational efficiency, and raising audit readiness, while reducing risk and enabling faster, more reliable commercialization today and well into the future.
“This investment goes well beyond incremental upgrades or technical improvements—it reflects our commitment to delivering real value for our customers,” says Maximilian Fattinger, VP Premix at dsm-firmenich. “By taking a generational step forward in premix excellence, we are raising the bar for quality, safety, and reliability, so customers can count on consistent performance and dependable supply. Established in 1995, the Schenectady site now enters its next chapter as a future‑ready facility built to support higher service levels and long‑term partnership. It underscores our belief that trust in premix solutions is earned by investing ahead of customer needs and setting uncompromising standards.”
Built for uncompromising quality, operational confidence, and sustainable progress
Purpose-built for excellence, the upgraded Schenectady facility gives customers complete confidence at every stage of premix production. At the heart of the transformation are three critical pillars:
Together, these upgrades align Schenectady with evolving regulatory and safety expectations and increasingly rigorous customer audits, while helping customers reduce operation risk and maintain continuity as standards evolve.
A platform for growth, trust, and collaboration
Beyond strengthening premix quality and operations, the flagship Schenectady plant serves as a platform for deeper customer engagement. It opens its doors to visitors, offering a transparent, behind-the-scenes look at the systems, standards, and expertise that underpin dsm-firmenich’s commitment to uncompromising quality, safety, and continuous improvement.
© 2026 Biopharma Boardroom. All Rights Reserved.